6 Results

People

  1. Nikolov
    Nikolov
  2. Saha
    Saha
  3. De Stanchina
    De Stanchina
  4. Himanen
    Himanen
  5. Robev
    Robev
  6. Besmer
    Besmer
  7. De La Cruz
    De La Cruz
  8. Goldgur
    Goldgur
  9. Kalidindi
    Kalidindi
  10. Kawaguchi
    Kawaguchi

Groups

  1. Sloan Kettering Institute Faculty (4)
  2. Sloan Kettering Institute Postdocs (4)
  3. GSK Faculty (3)
  4. Structural Biology Program Faculty (3)
  5. Radiochemistry and Imaging Sciences Service (2)
  6. Radiology, Department of (2)
  7. Developmental Biology Program Faculty (1)
  1. "adam17"
Formats
  1. Journal Article (5)
  2. Review (1)
Groups
  1. Sloan Kettering Institute Faculty (4)
  2. Sloan Kettering Institute Postdocs (4)
  3. GSK Faculty (3)
  4. Structural Biology Program Faculty (3)
  5. Radiochemistry and Imaging Sciences Service (2)
  6. Radiology, Department of (2)

More Groups

People
  1. Dimitar Nikolov (3)
  2. Juha Himanen (3)
  3. Nayanendu Saha (3)
  4. Dorothea Robev (2)
  5. Elisa De Stanchina (2)
  6. Darren Veach (1)

More People

Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2021 (1)
  4. 2019 (1)
  5. 2017 (1)
  6. 2007 (1)
Publications
  1. Journal of Cell Science (2)
  2. Biomedicine and Pharmacotherapy (1)
  3. Cancer Letters (1)
  4. Diagnostics (1)
  5. Translational Oncology (1)
Publishers
  1. Company of Biologists (2)
  2. Elsevier Inc. (1)
  3. Elsevier Ireland Ltd. (1)
  4. Elsevier Science, Inc. (1)
  5. MDPI (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Fully human monoclonal antibody targeting the cysteine-rich substrate-interacting region of ADAM17 on cancer cells
    Journal Article

    Saha, N.; Lee, S. G.; Brockmann, E. C.; de la Cruz, M. J.; Goldgur, Y.; Mendoza, R. P.; de Stanchina, E.; Love, T. M.; Marvald, J.; Xu, Y.; more...
    Biomedicine and Pharmacotherapy (2024)

    Fulltext@MSK | Save
  • Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells
    Journal Article

    Saha, N.; Xu, K.; Zhu, Z.; Robev, D.; Kalidindi, T.; Xu, Y.; Himanen, J.; de Stanchina, E.; Pillarsetty, N. V. K.; Dimitrov, D. S.; more...
    Translational Oncology (2022)

    Fulltext@MSK | Save
  • Regulation of platelet-derived ADAM17: A biomarker approach for breast cancer?
    Journal Article

    Zhou, Y.; Heitmann, J. S.; Kropp, K. N.; Hinterleitner, M.; Koch, A.; Hartkopf, A. D.; Salih, H. R.; Hinterleitner, C.; Maurer, S.
    Diagnostics (2021)

    Fulltext@MSK | Save
  • ADAM proteases: Emerging role and targeting of the non-catalytic domains
    Review

    Saha, N.; Robev, D.; Himanen, J. P.; Nikolov, D. B.
    Cancer Letters (2019)

    Fulltext@MSK | Save
  • Structural modeling defines transmembrane residues in ADAM17 that are crucial for Rhbdf2-ADAM17-dependent proteolysis
    Journal Article

    Li, X.; Maretzky, T.; Perez-Aguilar, J. M.; Monette, S.; Weskamp, G.; Le Gall, S.; Beutler, B.; Weinstein, H.; Blobel, C. P.
    Journal of Cell Science (2017)

    Fulltext@MSK | Save
  • Different ADAMs have distinct influences on Kit ligand processing: Phorbol-ester-stimulated ectodomain shedding of Kitl1 by ADAM17 is reduced by ADAM19
    Journal Article

    Kawaguchi, N.; Horiuchi, K.; Becherer, J. D.; Toyama, Y.; Besmer, P.; Blobel, C. P.
    Journal of Cell Science (2007)

    Fulltext@MSK | Save